Home >> Company >> Team

Ken Harris, President & Chief Executive Officer
Ken has over 30 years of experience in the biotechnology, cell therapy, and medical device industries.  Prior to joining Bell, Ken had co-Founded TotipotentRX Corporation in 2008, and served as its Chairman and CEO before merging the company with ThermoGenesis Corp. and funding and listing the new entity as Cesca Therapeutics on the
Caleb B. Bell III, Ph.D., Co-Founder and Chief Technology Officer
Caleb serves as the CTO and co-Founder of Bell BioSystems, and additionally held the CEO role through June 2017.  Under Caleb’s leadership, Bell Biosystems has been recognized by the White House for its “Breakthrough” in life science technologies, as a 2014 Rising Star by BayBio, and as a “biotech on the cusp
Dan Bell, Co-Founder and Interim Chief Financial Officer
Dan co-founded Bell Biosystems and currently oversees all financial and operations matters.  Dan previously served in operations, sales, and marketing roles at retail energy startup Energy Plus.  Joining Energy Plus as its 8th employee, Dan co-led the launch and expansion of a business line that grew to $30M+ in revenue within t
Ertan Ozyamak, Ph.D., Lead Manufacturing Microbiologist
Dr. Ozyamak has broad training in bacterial physiology, genetics, cell biology and biochemistry, and is primarily responsible for Magnelle production. Prior to joining Bell Biosystems, Ertan gained extensive expertise on the biology of magnetotactic bacteria during postdoctoral research at the University of California, Berkeley. He has pi
Matt Reichlen, Ph.D., Lead Research Microbiologist
Dr. Reichlen leads our microbiology research group.  Matt  has extensive training in microbial physiology and molecular genetics working with diverse microorganisms of both clinical and industrial importance. Prior to joining Bell, Matt did postdoctoral research at the University of Colorado School of Medicine investigating the
Stuart Gibb, Ph.D., Lead Eukaryotic Scientist
Dr. Gibb  leads our cell therapy research group.  Stuart  has extensive experience in research and GMP production of eukaryotic cells for clinical applications . Prior to joining Bell, Stuart led the UCSF Blood Systems production facility for cell therapies for clinical trials in traumatic brain injury.  Stuart co
Contact Us Sitemap Terms of Use
Follow Bell Biosystems
© 2018 Bell Biosystems. All rights are reserved
Website Security Test